News & Updates

Adding pembrolizumab to standard chemotherapy resulted in a favourable overall survival (OS) benefit in patients with advanced or recurrent endometrial cancer compared with chemotherapy alone, regardless of mismatch repair (MMR) status, according to a key prespecified secondary analysis of the NRG-GY018 trial presented at the SGO 2024.

Many adult survivors of childhood cancer do not adhere to a healthful dietary pattern, particularly racial minorities and those with a lower socioeconomic status, reveals a study.

Children with Wilms tumour (WT) treated with abdominal radiation therapy (RT) may opt to receive unilateral flank radiation instead of whole abdominal and pelvic RT (WAPRT) for contained rupture or spillage, suggests a study.

The University of Hong Kong’s (HKU) comprehensive analysis of lung cancer trends in Hong Kong between 2002 and 2021 reports an increase in crude incidence, a decline in age-standardized incidence, and an increase in survival rates, which, however, remained <40 percent at 5 years.   

New drug applications approved by US FDA as of 1-15 March 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.